With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...
In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...
Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...
Investor's Business Daily on MSN4d
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASHMadrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.
Zacks.com on MSN4d
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock UpMadrigal Pharmaceuticals MDGL reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate ...
Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...
In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...
5d
Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback